Related content

Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: An open-label, 12- to 36-month continuation study

By Edward Hogan R.   Garnett W.R.   Thadani V.M.   Carbatrol Study Group  

Clinical Therapeutics, Vol. 25, Iss. 10, 2003-10 ,pp. : 2586-2596

Elsevier

Access to resources Recommend Favorite

Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: Results of a European multicenter, open-label study of patient preference

By Stroberg P.   Murphy A.   Costigan T.  

Clinical Therapeutics, Vol. 25, Iss. 11, 2003-11 ,pp. : 2724-2737

Elsevier

Access to resources Recommend Favorite

A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus

By Korytkowski M.   Bell D.   Jacobsen C.   Suwannasari R.   FlexPenR Study Team  

Clinical Therapeutics, Vol. 25, Iss. 11, 2003-11 ,pp. : 2836-2848

Elsevier

Access to resources Recommend Favorite

Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study

By Eke F.U.   Anochie I.  

Current Therapeutic Research, Vol. 64, Iss. 8, 2003-09 ,pp. : 616-625

Elsevier

Access to resources Recommend Favorite

Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study

By Shimizu M.   Ogawa K.   Sasaki H.   Uehara Y.   Otsuka Y.   Okumura H.   Kusaka M.   Hasuda T.   Yamada T.   Mochizuki S.  

Current Therapeutic Research, Vol. 64, Iss. 9, 2003-11 ,pp. : 707-714

Elsevier

Access to resources Recommend Favorite